CN Patent

CN110198739B — 一种pd-l1抗体药物组合物及其用途

Assigned to Suzhou Suncadia Biopharmaceuticals Co Ltd · Expires 2023-04-04 · 3y expired

What this patent protects

本发明提供了一种PD‑L1抗体药物组合物及其用途。具体而言，本发明提供了一种药物组合物，其包含琥珀酸盐缓冲剂中的PD‑L1抗体或其抗原结合片段。除此之外，该药物组合物还可含有糖和非离子表面活性剂。

USPTO Abstract

本发明提供了一种PD‑L1抗体药物组合物及其用途。具体而言，本发明提供了一种药物组合物，其包含琥珀酸盐缓冲剂中的PD‑L1抗体或其抗原结合片段。除此之外，该药物组合物还可含有糖和非离子表面活性剂。

Drugs covered by this patent

Patent Metadata

Patent number
CN110198739B
Jurisdiction
CN
Classification
—
Expires
2023-04-04
Drug substance claim
No
Drug product claim
No
Assignee
Suzhou Suncadia Biopharmaceuticals Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.